Novo Nordisk Warned us For Years About Synthesized Semaglutide. Now They Want In.
Novo Nordisk has spent years warning patients, regulators, lawmakers, and courts about the risks of synthetic semaglutide. Now, as patents begin to expire and China’s pharmaceutical industry becomes increasingly important, Novo may be staring at a very uncomfortable question: what happens if synthetic semaglutide suddenly makes sense when Novo is the one making it?
In this week’s episode of The Weekly Dose, I dig into Novo’s long-running recombinant-versus-synthetic semaglutide argument, the lawsuits and FDA petitions built around it, and a clip from more than 16 months ago showing that we were covering this exact issue long before it became part of the mainstream conversation. Novo Warned Us About Synthetic Semaglutide_ Now This_.txt
We also break down Pfizer’s decision to kill two clinical-stage obesity drugs, including an oral GLP-1 acquired through its $10 billion Metsera deal, the strange science behind GIP receptor antagonism, and why Pfizer’s remaining obesity pipeline still deserves attention. Plus, Wall Street is looking at Eli Lilly’s obesity-fueled rally and asking just how big this market can get.
In this episode:
00:00 Novo’s synthetic semaglutide problem
02:00 VoaFit sponsor message
03:30 The 16-month-old On The Pen receipt
05:00 Recombinant vs. synthetic semaglutide
07:00 Novo’s FDA, legal, and political strategy
09:00 Pfizer kills two obesity drugs
11:00 What happened to Metsera’s oral pipeline?
13:00 The GIP agonist vs. antagonist paradox
15:00 Why China matters to Pfizer and Novo
17:00 Could Novo eventually make synthetic semaglutide?
18:30 What comes next for Lilly, Novo, and Pfizer
The big question: If Novo Nordisk eventually launches its own synthetically manufactured semaglutide, does that change how you view the arguments it has made against compounded semaglutide over the last several years?
Comment below. I want to know where you land.
More obesity medicine news and analysis: OnThePen.com
All my links, socials, and resources: linktr.ee/manonthemounjaro
This episode is sponsored by VoaFit. Learn more at voafit.com/otp.
#GLP1 #Semaglutide #Ozempic #Wegovy #NovoNordisk #CompoundedSemaglutide #ObesityMedicine #Pfizer #EliLilly #Mounjaro #Zepbound #Metsera
In this week’s episode of The Weekly Dose, I dig into Novo’s long-running recombinant-versus-synthetic semaglutide argument, the lawsuits and FDA petitions built around it, and a clip from more than 16 months ago showing that we were covering this exact issue long before it became part of the mainstream conversation. Novo Warned Us About Synthetic Semaglutide_ Now This_.txt
We also break down Pfizer’s decision to kill two clinical-stage obesity drugs, including an oral GLP-1 acquired through its $10 billion Metsera deal, the strange science behind GIP receptor antagonism, and why Pfizer’s remaining obesity pipeline still deserves attention. Plus, Wall Street is looking at Eli Lilly’s obesity-fueled rally and asking just how big this market can get.
In this episode:
00:00 Novo’s synthetic semaglutide problem
02:00 VoaFit sponsor message
03:30 The 16-month-old On The Pen receipt
05:00 Recombinant vs. synthetic semaglutide
07:00 Novo’s FDA, legal, and political strategy
09:00 Pfizer kills two obesity drugs
11:00 What happened to Metsera’s oral pipeline?
13:00 The GIP agonist vs. antagonist paradox
15:00 Why China matters to Pfizer and Novo
17:00 Could Novo eventually make synthetic semaglutide?
18:30 What comes next for Lilly, Novo, and Pfizer
The big question: If Novo Nordisk eventually launches its own synthetically manufactured semaglutide, does that change how you view the arguments it has made against compounded semaglutide over the last several years?
Comment below. I want to know where you land.
More obesity medicine news and analysis: OnThePen.com
All my links, socials, and resources: linktr.ee/manonthemounjaro
This episode is sponsored by VoaFit. Learn more at voafit.com/otp.
#GLP1 #Semaglutide #Ozempic #Wegovy #NovoNordisk #CompoundedSemaglutide #ObesityMedicine #Pfizer #EliLilly #Mounjaro #Zepbound #Metsera
Loading content...
Read the full transcript
Matterfact has every podcast on Apple Podcasts and Spotify: 700K+ channels, 120M+ episodes.
The candid version is on a podcast,
not the earnings call.
Matterfact turns the conversations your coverage is already having into a searchable, citable record — across every episode, not just this one.